Figure 4.

Kaplan-Meier survival curves of male and female patients with EGFR wild-type lung adenocarcinoma according to the immunoreactivity results for aromatase and ERβ. A. Recurrence-free survival (RFS) of males stratified by high versus low expression of aromatase. B. RFS of females stratified by high versus low expression of aromatase. C. RFS of males stratified by positive versus negative expression of ERβ. D. RFS of females stratified by positive versus negative expression of ERβ. E. RFS of males stratified by combined high expression of aromatase/positive expression of ERβ versus combined low expression of aromatase/negative expression of ERβ versus others. F. RFS of females stratified by combined high expression of aromatase/positive expression of ERβ versus combined low expression of aromatase/negative expression of ERβ versus others.